Transcriptome Profiling Analysis of Breast Cancer Cell MCF-7 Treated by Sesamol.

Content Provider	Europe PMC
Author	Wu, Jiafa Luo, Dongping Xu, Jiayun
Copyright Year	2023
Abstract	BackgroundBreast cancer is a highly malignant tumor that affects a large number of women worldwide. Sesamol, a natural compound, has been shown to exhibit inhibitory effects on various tumors, including breast cancer. However, the underlying mechanism of its action has not been fully explored. In this study, we aimed to investigate the effect of sesamol on the transcriptome of MCF-7 breast cancer cells, in order to better understand its potential as an anti-cancer agent.MethodsThe transcriptome profiles of MCF-7 breast cancer cells treated with sesamol were analyzed using Illumina deep-sequencing. The differentially expressed genes (DEGs) between the control and sesamol-treated groups were identified, and GO and KEGG pathway analyses of these DEGs were conducted using ClueGO. Protein–protein interaction (PPI) network of DEGs was mapped on STRING database and visualized by Cytoscape software. Hub genes in the network were screened by Cytohubba plugin of Cytoscape. Prognostic values of hub genes were analyses by the online Kaplan–Meier plotter and validated by qRT-PCR in MCF-7 cells.ResultsThe results of the study showed that sesamol treatment had a significant effect on the transcriptome of MCF-7 cells, with a total of 351 DEGs identified. Functional enrichment analyses of DEGs revealed their involvement in extracellular matrix (ECM) remodeling, fatty acid metabolism and monocyte chemotaxis. The protein–protein interaction (PPI) network analysis of DEGs resulted in the identification of 10 hub genes, namely IGF2, MMP1, MSLN, CXCL10, WT1, ITGAL, PLD1, MME, TWIST1, and FOXA2. Survival analysis showed that MMP1 and ITGAL were significantly associated with overall survival (OS) and recovery-free survival (RFS) in breast cancer patients.ConclusionSesamol may play important roles in extracellular matrix (ECM) remodeling, fatty acid metabolism and cell cycle of MCF-7.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10238551&blobtype=pdf
Page Count	11
Journal	Breast Cancer : Targets and Therapy [Breast Cancer (Dove Med Press)]
Volume Number	15
PubMed Central reference number	PMC10238551
PubMed reference number	37274057
e-ISSN	11791314
DOI	10.2147/bctt.s392480
Language	English
Publisher	Dove
Publisher Date	2023-05-29
Access Restriction	Open
Rights License	This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2023 Wu et al.
Subject Keyword	breast cancer cells sesamol transcriptome differentially expressed genes GO and KEGG pathway analyses
Content Type	Text
Resource Type	Article
Subject	Oncology